MSLE
Satellos Bioscience Inc

256
Mkt Cap
$129.15M
Volume
68,268.00
52W High
$13.39
52W Low
$4.53
PE Ratio
-3.59
MSLE Fundamentals
Price
$6.50
Prev Close
$6.20
Open
$6.23
50D MA
$9.60
Beta
0.14
Avg. Volume
125,527.76
EPS (Annual)
-$1.70
P/B
3.45
Rev/Employee
$0.00
$56.62
Loading...
Loading...
News
all
press releases
Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts
Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) has been assigned an average rating of "Hold" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners
Leerink Partners initiated coverage on shares of Satellos Bioscience in a research report on Monday. They set an "outperform" rating and a $20.00 price target on the stock...
MarketBeat·4d ago
News Placeholder
Q2 EPS Estimate for Satellos Bioscience Increased by Analyst
Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Satellos Bioscience in a report issued on Monday, March 30th. HC...
MarketBeat·9d ago
News Placeholder
FY2030 Earnings Forecast for MSLE Issued By HC Wainwright
Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research note issued to investors on Monday, March 30th. HC Wainwright analyst A. He expects that the company will earn $0.34 per share...
MarketBeat·10d ago
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00
HC Wainwright boosted their price objective on shares of Satellos Bioscience from $1.20 to $11.00 and gave the stock a "buy" rating in a research report on Monday...
MarketBeat·11d ago
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results
Satellos Bioscience (NASDAQ:MSLE - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.36...
MarketBeat·13d ago
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Satellos Bioscience to a "strong sell" rating in a research note on Saturday...
MarketBeat·28d ago
News Placeholder
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday. They set an "overweight" rating on the stock...
MarketBeat·1mo ago
News Placeholder
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·2mo ago
News Placeholder
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...
Business Wire·2mo ago
<
1
2
...
>

Latest MSLE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.